There was a strong trend for a reduced prevalence of hypertension and dyslipidemia with increasing number of protective factors with those who scored four or more factors having approximately one ...

Active in clinical trials include novel therapeutic agents for hypertension, dyslipidemia, diabetes/insulin resistance and obesity. the role of inflammation in the response to acute vascular injury ...

The Gemini Study was a 14-week, open-label, non-comparative, office-based, multicenter trial to evaluate single-pill therapy in the treatment of concomitant hypertension and dyslipidemia.

During the past few years we are hearing more and more about our society being obese and overweight. According to the Health, United States 2005, a CDC report, 31 percent of adult Americans are ...

Unadjusted incidence rates of type 2 diabetes, hypertension, dyslipidemia, weight-loss bariatric surgery, and depression or anxiety outcomes tended to decrease with better treatment response but were ...